Login to Your Account

Anything but wingless, Oncomed slates phase II bounty in big year ahead

By Randy Osborne
Staff Writer

Friday, August 29, 2014
Oncomed Pharmaceuticals Inc.'s stoppage in June of phase Ib trials because of bone-related adverse events with a pair of candidates did little to dampen the enthusiasm of analysts for the firm, and last week's lift of the partial clinical hold on vantictumab (OMP-18R5) only made the picture brighter.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription